Apricot Capital

07/13/2023 | Press release | Archived content

CirCode Announces Research Agreement with Pfizer to Explore the Potential of Circular RNA Therapeuti

Shanghai, China - CirCode Biomed announced a research agreement with Pfizer Inc. to explore the potential of CirCode's Circular RNA therapeutics technology. The aim of the agreement is to deepen current knowledge of how to translate circular RNA technology into potential drug candidates and will make use of CirCode's proprietary circular RNA platform and Pfizer's broad expertise in drug discovery.
Apricot Capital published this content on July 13, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 27, 2026 at 06:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]